CompletedPhase 3NCT03129646

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Drugs for Neglected Diseases
Principal Investigator
Jane Mbui, MD
Kenya Medical Research Institute
Intervention
Miltefosine(drug)
Enrollment
439 target
Eligibility
4-50 years · All sexes
Timeline
2018 – 2020

Study locations (7)

Collaborators

The Netherlands Cancer Institute · The Institute of Endemic Diseases (IEND), University of Khartoum · Kenya Medical Research Institute · Makerere University · University of Gondar

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03129646 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis →

← Back to all trials